RVMD
Revolution Medicines, Inc. Common Stock
$209.47
장중 · Vol 298.2K · 52주 $37.88–$224.31 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $204.01 · Aug 31, 2026
RVMD 가격 추세
종가
$204.01
시가
$205.01
고가
$206.30
저가
$200.53
30초 브리핑
RVMD 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 92%
연중 고점권입니다. 추세 강도와 돌파 실패 위험을 함께 확인하세요.
Forward P/E -33.9배
업종 피어 비교 전에는 고평가·저평가를 단정하기 어렵습니다.
20일 평균의 1.6배
평소보다 거래가 활발해 가격 움직임의 확인 강도가 높습니다.
2026-11-04
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
RVMD 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
700 Saginaw Drive · Redwood City, CA, United States · 직원 883명
시가총액
$44.06B
Trailing P/E
—
최근 12개월 이익 기준
Forward P/E
-33.9
EPS (TTM)
$-8.78
배당 수익률
—
배당성향
0.0%
베타
1.40
시장보다 민감
ROE
-79.1%
P/B
27.43
EV/EBITDA
-25.8
52주 범위
$37.88 – $224.31
현재 위치 92%
거래량
2.12M
20일 평균 1.33M · 1.6배
애널리스트 의견
매수 95%
총 22명 · 0m
DITM LEAPS Analysis
RVMD 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RVMD280121C00105000 | 1/21/28 · 1.4Y | $105.00 | $113.00 | 1.7x | 0.9115 | 9.9% | 4.42% | 64.94% | 48 | 79.66 | |
| RVMD280121C00110000 | 1/21/28 · 1.4Y | $110.00 | $109.00 | 1.7x | 0.9032 | 11.2% | 4.59% | 63.67% | 90 | 78.85 | |
| RVMD280121C00120000 | 1/21/28 · 1.4Y | $120.00 | $101.65 | 1.8x | 0.8838 | 14.6% | 4.62% | 62.20% | 305 | 76.42 | |
| RVMD280121C00115000 | 1/21/28 · 1.4Y | $115.00 | $110.00 | 1.7x | 0.8828 | 16.5% | 4.55% | 72.13% | 52 | 71.65 | |
| RVMD280121C00130000 | 1/21/28 · 1.4Y | $130.00 | $95.25 | 1.9x | 0.8614 | 19.4% | 4.72% | 61.94% | 149 | 70.87 | |
| RVMD280121C00125000 | 1/21/28 · 1.4Y | $125.00 | $99.00 | 1.8x | 0.8713 | 17.4% | 5.05% | 63.14% | 24 | 70.78 | |
| RVMD280121C00135000 | 1/21/28 · 1.4Y | $135.00 | $91.90 | 1.9x | 0.8503 | 21.9% | 5.22% | 61.34% | 269 | 69.00 | |
| RVMD280121C00140000 | 1/21/28 · 1.4Y | $140.00 | $89.45 | 1.9x | 0.8376 | 25.3% | 3.47% | 62.04% | 248 | 66.24 | |
| RVMD280121C00145000 | 1/21/28 · 1.4Y | $145.00 | $86.00 | 2.0x | 0.8264 | 28.1% | 5.81% | 61.05% | 56 | 61.71 | |
| RVMD271119C00140000 | 11/19/27 · 1.2Y | $140.00 | $86.50 | 2.0x | 0.8403 | 22.8% | 5.78% | 61.40% | 1 | 61.33 | |
| RVMD280121C00150000 | 1/21/28 · 1.4Y | $150.00 | $82.95 | 2.0x | 0.8144 | 31.5% | 5.91% | 60.57% | 200 | 60.16 | |
| RVMD280121C00155000 | 1/21/28 · 1.4Y | $155.00 | $80.00 | 2.1x | 0.8022 | 35.2% | 6.25% | 60.14% | 144 | 56.77 | |
| RVMD280121C00160000 | 1/21/28 · 1.4Y | $160.00 | $77.25 | 2.1x | 0.7896 | 39.4% | 5.83% | 59.89% | 158 | 53.76 | |
| RVMD280121C00165000 | 1/21/28 · 1.4Y | $165.00 | $74.50 | 2.2x | 0.7769 | 43.9% | 5.37% | 59.53% | 44 | 49.28 | |
| RVMD280121C00170000 | 1/21/28 · 1.4Y | $170.00 | $71.65 | 2.2x | 0.7641 | 48.6% | 6.56% | 58.97% | 201 | 47.04 | |
| RVMD271119C00165000 | 11/19/27 · 1.2Y | $165.00 | $71.50 | 2.2x | 0.7751 | 41.5% | 6.99% | 59.48% | 4 | 46.92 | |
| RVMD280121C00175000 | 1/21/28 · 1.4Y | $175.00 | $69.25 | 2.2x | 0.7510 | 54.1% | 6.50% | 58.88% | 31 | 41.34 |
재무제표
RVMD 연간 손익·현금흐름·재무상태
매출 성장률
—
최근 연간 YoY
EPS 성장률
-66.2%
최근 연간 YoY
영업이익률
—
최근 연간
FCF 마진
—
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $0.00 | $0.00-100.0% | $11.58M-67.3% | $35.38M |
| 매출총이익 | — | — | — | — |
| 영업이익 | -$1.18B-71.5% | -$689.52M-41.5% | -$487.19M-88.6% | -$258.28M |
| 순이익 | -$1.13B-88.5% | -$600.09M-37.5% | -$436.37M-75.5% | -$248.71M |
| 희석 EPS | $-5.95-66.2% | $-3.58+7.3% | $-3.86-25.3% | $-3.08 |
| EBITDA | -$1.09B-85.1% | -$589.02M-36.8% | -$430.58M-73.2% | -$248.62M |
| 영업현금흐름 | -$897.74M-61.0% | -$557.44M-59.0% | -$350.57M-56.2% | -$224.40M |
| 잉여현금흐름 | -$913.73M-60.9% | -$567.74M-58.5% | -$358.30M-52.3% | -$235.22M |
| 총자산 | $2.35B-8.0% | $2.56B+24.1% | $2.06B+153.9% | $811.93M |
| 총부채 | $158.70M+16.8% | $135.84M+54.5% | $87.94M+37.0% | $64.20M |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
RVMD 실적·배당 일정
매출 하단
0
EPS 하단
$-3.26
매출 상단
$51.50M
실적 발표일
2026-11-04
D-64
EPS 상단
$-2.12
매출 컨센서스
$13.99M
EPS 컨센서스
$-2.44
뉴스
RVMD 관련 최신 기사
규제·법률Patients with the deadliest cancer finally have something that works
The FDA just cleared a first-of-its-kind pancreatic cancer pill from Revolution Medicines.
TheStreet · Aug 29, 2026
일반Pharma Industry Stares Down Biggest Patent Cliff in Decades
For drugmakers, a clock starts before a drug is even approved: Patents run out, lower-priced copycats flood in and sales collapse. The pharma industry is entering its biggest wave of patent expirations in decades. The world’s bestselling drug in 2025, Merck’s cancer immunotherapy Keytruda, loses U.S. patent protection in 2028, and nearly every pharma company has at least one blockbuster drug that will go off patent in the next five years.
The Wall Street Journal · Aug 29, 2026
일반Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?
Incyte Corporation (NASDAQ:INCY) generated buzz on August 19 when RBC Capital highlighted upcoming ESMO data for its KRAS G12D inhibitor ‘734 in combination with mFOLFIRINOX and GemNabP. RBC noted that while prior data was too limited for firm conclusions, the update should look “very competitive” and support ongoing Phase 3 efforts in first-line pancreatic ductal […]
Insider Monkey · Aug 28, 2026
규제·법률Revolution Medicines (RVMD) Made Pancreatic-Cancer History. At $47B Valuation, the Market Already Assumed It
Revolution Medicines, Inc. (NASDAQ:RVMD) touched an all-time high above $224 on August 27, 2026, following FDA approval of Rasonque (daraxonrasib) – the first broad RAS-targeted therapy cleared for metastatic pancreatic cancer. Creating a milestone, the approval came roughly five weeks after filing under the agency’s national priority voucher. The pivotal RASolute 302 trial nearly doubled […]
Insider Monkey · Aug 28, 2026
규제·법률Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer
Revolution Medicines (NASDAQ:RVMD) said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma. The oral, once-daily RAS(ON) multi-selective inhibitor is approved for adults with metastatic pancreati
MarketBeat · Aug 28, 2026
- 제품·기술
Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says
Revolution Medicines (RVMD) should post "strong launch numbers" for pancreatic cancer drug Rasonque
MT Newswires · Aug 28, 2026
- 규제·법률
New pancreatic cancer drug carries a $39,800 monthly list price: What to know
The FDA has approved a new pill for one of the most common forms of pancreatic cancer. What to know about managing the financial impact of a cancer diagnosis.
Yahoo Personal Finance · Aug 28, 2026
규제·법률Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?
The biotech's Rasonque is already available for prescription.
Motley Fool · Aug 28, 2026
제품·기술Revolution Medicines (RVMD) After RASONQUE Approval Is The Valuation Story Still Intact
Revolution Medicines (RVMD) is in focus after the U.S. Food and Drug Administration approved RASONQUE, a once daily oral RAS inhibitor for certain adults with metastatic pancreatic adenocarcinoma following prior treatment. Revolution Medicines' share price has reacted strongly around these developments, with a 1-month share price return of 22.24% and a 3-month share price return of 40.43% helping lift the stock to US$221.15. The 1-year total shareholder return is also very large, indicating...
Simply Wall St. · Aug 28, 2026
규제·법률Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent
Revolution Medicines attracted takeover interest but decided to go it alone. This week’s FDA approval of its pancreatic cancer pill is the payoff.
The Wall Street Journal · Aug 28, 2026
홀더
RVMD 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
101.1%
기관 보유 (유동주식)
103.0%
내부자 보유
1.9%
기관 수
924
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 13.70M | $2.82B | 6.4% | 22.1% | Jun 30, 2026 |
| Farallon Capital Management LLC | 13.55M | $2.79B | 6.3% | -0.4% | Jun 30, 2026 |
| FMR, LLC | 12.20M | $2.51B | 5.7% | 44.1% | Jun 30, 2026 |
| Baker Bros. Advisors, LP | 11.44M | $2.35B | 5.3% | 19.8% | Jun 30, 2026 |
| Jupiter Topco LLC | 10.74M | $2.21B | 5.0% | 100.0% | Jun 30, 2026 |
| Darwin Global Management, Ltd. | 10.63M | $2.19B | 5.0% | 380.8% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 9.09M | $1.87B | 4.2% | 8.7% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 8.29M | $1.71B | 3.9% | 10.6% | Jun 30, 2026 |
| Nextech Invest, Ltd. | 7.60M | $1.56B | 3.5% | 0.0% | Jun 30, 2026 |
| Paradigm Biocapital Advisors LP | 6.36M | $1.31B | 3.0% | -4.4% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.